91 related articles for article (PubMed ID: 17516484)
1. Efficacy and tolerability of Entacapone versus Cabergoline in parkinsonian patients suffering from wearing-off.
Deuschl G; Vaitkus A; Fox GC; Roscher T; Schremmer D; Gordin A;
Mov Disord; 2007 Aug; 22(11):1550-5. PubMed ID: 17516484
[TBL] [Abstract][Full Text] [Related]
2. Placebo-controlled, double-blind dose-finding study of entacapone in fluctuating parkinsonian patients.
Mizuno Y; Kanazawa I; Kuno S; Yanagisawa N; Yamamoto M; Kondo T
Mov Disord; 2007 Jan; 22(1):75-80. PubMed ID: 17094103
[TBL] [Abstract][Full Text] [Related]
3. Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease.
Hauser RA; Panisset M; Abbruzzese G; Mancione L; Dronamraju N; Kakarieka A;
Mov Disord; 2009 Mar; 24(4):541-50. PubMed ID: 19058133
[TBL] [Abstract][Full Text] [Related]
4. Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.
Fung VS; Herawati L; Wan Y; ;
Mov Disord; 2009 Jan; 24(1):25-31. PubMed ID: 18846551
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre study.
Fénelon G; Giménez-Roldán S; Montastruc JL; Bermejo F; Durif F; Bourdeix I; Péré JJ; Galiano L; Schadrack J
J Neural Transm (Vienna); 2003 Mar; 110(3):239-51. PubMed ID: 12658373
[TBL] [Abstract][Full Text] [Related]
6. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations.
Reichmann H; Boas J; Macmahon D; Myllyla V; Hakala A; Reinikainen K;
Acta Neurol Scand; 2005 Jan; 111(1):21-8. PubMed ID: 15595934
[TBL] [Abstract][Full Text] [Related]
8. Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients.
Stocchi F; Hsu A; Khanna S; Ellenbogen A; Mahler A; Liang G; Dillmann U; Rubens R; Kell S; Gupta S
Parkinsonism Relat Disord; 2014 Dec; 20(12):1335-40. PubMed ID: 25306200
[TBL] [Abstract][Full Text] [Related]
9. An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off.
Koller W; Guarnieri M; Hubble J; Rabinowicz AL; Silver D
J Neural Transm (Vienna); 2005 Feb; 112(2):221-30. PubMed ID: 15503197
[TBL] [Abstract][Full Text] [Related]
10. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease.
Olanow CW; Kieburtz K; Stern M; Watts R; Langston JW; Guarnieri M; Hubble J;
Arch Neurol; 2004 Oct; 61(10):1563-8. PubMed ID: 15477510
[TBL] [Abstract][Full Text] [Related]
11. Immediate versus delayed switch from levodopa/carbidopa to levodopa/carbidopa/entacapone: effects on motor function and quality of life in patients with Parkinson's disease with end-of-dose wearing off.
Lew MF; Somogyi M; McCague K; Welsh M;
Int J Neurosci; 2011 Nov; 121(11):605-13. PubMed ID: 21843110
[TBL] [Abstract][Full Text] [Related]
12. Naturalistic evaluation of entacapone in patients with signs and symptoms of L-dopa wearing-off .
Jog M; Panisset M; Suchowersky O; Réhel B; Schecter R
Curr Med Res Opin; 2008 Nov; 24(11):3207-15. PubMed ID: 18922214
[TBL] [Abstract][Full Text] [Related]
13. Employment, medical absenteeism, and disability perception in Parkinson's disease: A pilot double-blind, randomized, placebo-controlled study of entacapone adjunctive therapy.
Korchounov A; Bogomazov G
Mov Disord; 2006 Dec; 21(12):2220-4. PubMed ID: 17044084
[TBL] [Abstract][Full Text] [Related]
14. Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment.
Brooks DJ; Agid Y; Eggert K; Widner H; Ostergaard K; Holopainen A;
Eur Neurol; 2005; 53(4):197-202. PubMed ID: 15970632
[TBL] [Abstract][Full Text] [Related]
15. Double-blind comparison of cabergoline and bromocriptine in Parkinson's disease patients with motor fluctuations.
Inzelberg R; Nisipeanu P; Rabey JM; Orlov E; Catz T; Kippervasser S; Schechtman E; Korczyn AD
Neurology; 1996 Sep; 47(3):785-8. PubMed ID: 8797480
[TBL] [Abstract][Full Text] [Related]
16. Perampanel in Parkinson disease fluctuations: a double-blind randomized trial with placebo and entacapone.
Rascol O; Barone P; Behari M; Emre M; Giladi N; Olanow CW; Ruzicka E; Bibbiani F; Squillacote D; Patten A; Tolosa E
Clin Neuropharmacol; 2012; 35(1):15-20. PubMed ID: 22222634
[TBL] [Abstract][Full Text] [Related]
17. [Motor impairment, in patients with severe Parkinson's disease, associated with dopaminergic hyperstimulation (entacapone)].
Vaamonde J; Ibáñez R; Hernández A; Gudín M; de Luis P; del Real MA
Neurologia; 2001 Feb; 16(2):81-4. PubMed ID: 11257935
[TBL] [Abstract][Full Text] [Related]
18. A single-blind cross over study investigating the efficacy of standard and controlled release levodopa in combination with entacapone in the treatment of end-of-dose effect in people with Parkinson's disease.
Iansek R; Danoudis M
Parkinsonism Relat Disord; 2011 Aug; 17(7):533-6. PubMed ID: 21576031
[TBL] [Abstract][Full Text] [Related]
19. Conversion from dopamine agonists to cabergoline: an open-label trial in 128 patients with advanced Parkinson disease.
Linazasoro G;
Clin Neuropharmacol; 2008; 31(1):19-24. PubMed ID: 18303487
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of levodopa with entacapone in Parkinson's disease patients suboptimally controlled with levodopa alone, in daily clinical practice: an international, multicentre, open-label study.
Gershanik O; Emre M; Bernhard G; Sauer D
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Sep; 27(6):963-71. PubMed ID: 14499313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
